MESO Mesoblast Limited

11.79
+0  (2%)
Previous Close 11.58
Open 11.87
Price To book 1.73
Market Cap 897.15M
Shares 76,094,000
Volume 27,563
Short Ratio 11.79
Av. Daily Volume 31,339

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Ongoing
MPC-06-ID
Chronic low back pain
Phase 3 trial to be completed 1H 2017.
MSC-100-IV
acute graft versus host disease (aGVHD) in children
Phase 2 data released August 2016. Partnership required for Phase 3 development.
MPC-300-IV
Rheumatoid arthritis
Noted April 10, 2017 that interim analysis has been completed - trial to continue as planned.
MPC-150-IM
Chronic heart failure (CHF)

Latest News

  1. Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Failure
  2. Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
  3. FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease
  4. Independent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Phase 3 Chronic Heart Failure Trial
  5. Mesoblast Raises US$40 Million
  6. Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy
  7. Mesoblast (MESO) Shares March Higher, Can It Continue?
  8. Mesoblast Ltd. :MESO-US: Earnings Analysis: Q2, 2017 By the Numbers : March 7, 2017
  9. FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Versus Host Disease
  10. Mesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 31, 2016
  11. Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast
  12. Durable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents
  13. Published Study Results Show That Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease in Model of Early Rheumatoid Arthritis
  14. Mesoblast Director Recognized by Peers for Cardiovascular Leadership
  15. Blog Coverage Mesoblast Receives Payment from Mallinckrodt
  16. ETFs with exposure to Mesoblast Ltd. : January 4, 2017
  17. Blog Coverage Mallinckrodt and Mesoblast Enter Into Equity Purchase Agreement
  18. Mallinckrodt enters $21 million equity purchase agreement with Mesoblast